供应商 · 经销商 · 生物技术衍生的化妆品与个人护理原料

Bloomage Biotechnology

华熙生物（Bloomage Biotech）的使命是让科技服务于人类健康：团队研究透明质酸及其衍生物的用途与应用已超过 25 年，是国际知名品牌，产品覆盖各类客户需求。

运营中中国亚洲成立 2000 核实于 2026-10-05

简介

Bloomage Biotechnology Corporation Limited (Bloomage Biotech, SSE STAR: 688363) is a China-based biotech/biomanufacturing company using fermentation and cross-link technologies to produce industrial-scale hyaluronic acid and other bioactive ingredients, serving pharma, medical devices/medical aesthetics, cosmetics, and functional foods. It was founded in 2000 and is domiciled in Jinan, Shandong. Core products include pharmaceutical/cosmetic/food-grade sodium hyaluronate (200+ specs), plus medical aesthetics/medical terminal products and nutrition/skin science transformation offerings (brands include BIOHYALUX, QUADHA, MedRepair, Bio-MESO, Bloomage Health). Public listing: STAR Market since 2019-11-06; major shareholder includes 华熙昕宇投资有限公司 (59.06%). 2024 revenue was 5.371 billion yuan, with R&D investment 466 million yuan; the company reported 2024 as active business year. Reported scale includes 320 tons HA production capacity by end-2019 and multiple factories/pilot lines; it also expanded into new bioactives (e.g., PDRN). Latest 2025-2026 developments: April 2025 approvals for hyaluronic-acid injection products with lidocaine and multi–amino-acid formulations were reported; a 2026 PDRN fermentation patent was granted in July 2026, with pharmaceutical-grade PDRN factory in Weihai expected to start production in Q3 2026 at ~2 metric tons/year, indicating continued operations.

Sources#

行业: 化妆品
主题: 透明质酸、胶原蛋白与化妆品生物活性成分
角色: 经销商 — “…ext-generation viscoelastic agent for ophthalmic and orthopedic applications. ( ) - Black Zero — China's first…”

供应的生物解决方案 1

D1	以发酵化妆品原料替代鲨鱼肝角鲨烯、鸡冠透明质酸和动物胶原蛋白

产品与服务

产品: BIOHYALUX; QUADHA; MedRepair; Bio-MESO; Bloomage Health; Hailida Sodium Hyaluronate Injection; Haishixin Sodium Hyaluronate Gel; Injection Sodium Hyaluronate Compound Solution; Black Zero; Shui Ji Qun

认证: EDQM CEP Certificate; FDA DMF registration; National Drug Approval Number; EcoVadis Global Supply Chain Sustainability Rating - Silver; CDP Global Environmental Information Disclosure - Climate Change B; CDP Global Environmental Information Disclosure - Water Security A-; MSCI ESG Rating - BB; CSI ESG Rating - AA; Sino-Sec ESG Rating - A; Wind ESG Rating - A

应用: pharmaceuticals · medical aesthetics · nutrition science · skin science · Personal care · Pharmaceutical materials · Nutrition and health · Anti-aging intervention · Tissue regeneration
认证（官网）: EDQM CEP Certificate · FDA DMF registration · National Drug Approval Number · EcoVadis Global Supply Chain Sustainability Rating - Silver · CDP Global Environmental Information Disclosure - Climate Change B · CDP Global Environmental Information Disclosure - Water Security A- · MSCI ESG Rating - BB · CSI ESG Rating - AA · Sino-Sec ESG Rating - A · Wind ESG Rating - A
客户与合作伙伴: Leading universities · Research institutions · Top hospitals · Pharmaceutical companies · Fortune 500 enterprises
生产基地: Jinan, Shandong Province — First factory established in 2005, covering 80 mu.; Hyaluronic Acid · Hainan — Technology Industrial Park commenced operations in 2023. · Xiangtan — Production Base commenced full-scale operations in 2024. · Jinan — pharmaceuticals, medical devices, skin care products, and medical-grade hyaluronic acid raw materials · Tianjin — multifunctional flexible bioactive raw material · Hainan — high-end medical devices and regenerative medicine products · Dongying — high-end pharmaceutical-grade and cost-effective products · Chaohu — ODM/OEM services for skin care cosmetics · Xiangtan — innovative medical devices featuring bioactive new ingredients · Hangzhou — nutritious and healthy food · No. 678 Tianchen Street, High-tech Zone, Jinan City, Shandong Province · 33rd Floor, Tower D, Bloomage International Center, No. A6 Jianguomen Outer Street, Chaoyang District, Beijing
产品（官网）: BIOHYALUX — A brand of cross-linked hyaluronic acid dermal filler. · QUADHA · MedRepair · Bio-MESO · Bloomage Health · Hailida Sodium Hyaluronate Injection — A prescription drug for osteoarthritis treatment. · Haishixin Sodium Hyaluronate Gel — An ophthalmic viscoelastic device for cataract surgery. · Injection Sodium Hyaluronate Compound Solution — A next-generation viscoelastic agent for ophthalmic and orthopedic applications. · Black Zero — China's first functional food brand centered on hyaluronic acid. · Shui Ji Qun — A hyaluronic acid-fortified drinking water. · HA and Its Derivatives — 介绍1 · PDRN — 介绍1

摘自公司官网: about · products · production · quality · rnd · leadership · contact · sustainability

子公司: Dongying Fustar Biotechnology Co., Ltd. (acquired/controlled; also described as Dongying First Biochem Industrial Co., Ltd.). · Subsidiaries established in the U.S., France, Japan, and South Korea. · Subsidiary in Japan. · Acquired Revitacare S.A. (France). · Beijing Yikang Biotechnology Engineering Co., Ltd. (51% controlling stake acquired).

新闻与状态 6

2026-08 最新状态: 自2024年起，公司进行战略性业务调整，包括组织精简、聚焦回归原材料与医疗器械；2026年8月新投产一座全球智能制造基地。 ↗ ↗ ↗
2026-04-28 Bloomage BioTechnology Corporation Limited announced that it expects to receive CNY 300 million in funding | MarketScreener
Bloomage BioTechnology Corporation Limited plans to raise up to CNY 300 million through a private placement of A shares, with up to 35 investors and a 6-month hold period, pending shareholder approval. The deal would allow issuance at least 80% of the 20-day …
2026-02-27 Bloomage Biotechnology says prelim 2025 net profit up 67.0% Y/Y | MarketScreener
Bloomage Biotechnology reports a preliminary 2025 net profit up about 67% year-over-year, indicating strong profit growth for the company. The firm focuses on hyaluronic acid and related bioactive products across materials, medical end products, skincare, and …
2026-01-21 Company News-Bloomage Biotech
Bloomage Biotech has secured Master File registration with China's NMPA (CMDE) for its Hyatrue cross-linked sodium hyaluronate powder, highlighting regulatory progress and a commitment to compliant, efficient medical-device materials. The product, enabled by …
2026-07-10 The PDRN Gold Rush: Where Does the Real Competitive Barrier Lie?
Bloomage Biotech has built a comprehensive, end-to-end PDRN platform—covering all three generations of PDRN technology, a broad patent portfolio (21+ filings), and collaborative standards work with China’s National Institute of Metrology—to position itself as …
2026-09-10 Tigermed-Jyton Supports China NMPA Approval of Aqualuna® ECM Filler
Bloomage Biotech received NMPA marketing approval for Aqualuna® ECM injectable, the first China-produced composite ECM filler for perioral wrinkles, highlighting its leadership in HA-based anti-aging tech and integrated end-to-end product development from R&D …
2026-04-29 Bloomage Biotech 2025 Revenue Falls 22% but Profit Surges
Bloomage Biotech posted a 2025 revenue drop of about 22% to 4.199 billion CNY, but net profit jumped about 68% to 292 million CNY due to aggressive cost cutting and expense compression, with R&D investment rising to 11.24% of revenue as it focuses on …

关系网络：股东、合作伙伴、同类

股权与投资方 5

子公司	Dongying Fustar Biotechnology Co., Ltd
子公司	Subsidiaries established in the U.S., France, Japan, and South Korea
子公司	Subsidiary in Japan
子公司	Acquired Revitacare S.A
子公司	Beijing Yikang Biotechnology Engineering Co., Ltd

身份与联系方式

联系方式、人员和法律信息仅向会员开放。

会员登录